Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Reaping an early harvest

PE Biosystems Group's $330 million stock acquisition of Third Wave Technologies Inc. raises the possibility that some of the best private companies - and hence the best of the IPO candidates - might be picked off before they have a chance to go public.

While Third Wave (Madison, Wis.) had not yet filed for an IPO, it was no secret that the developer of single nucleotide polymorphism (SNP) detection systems was an IPO candidate for the first half of this year.

But the surging prices of publicly held companies increase the attractiveness of paper to make acquisitions for both the purchaser and the selling shareholders. And the price that PEB is paying for Third Wave could make such deals attractive.

On the other

Read the full 1200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE